We believe that AI holds the key to discover the next generation of tissue-based biomarkers to drastically improve how cancer and other complex diseases are diagnosed and treated. Our mission is to support the discovery and validation of these biomarkers, and to develop them into diagnostic products for global use in clinics and labs.
Our patented “Explainable AI” approach allows us to overcome conventional “black box” limitations of end-to-end AI models. A proprietary cell detection and classification approach enables us to dig deep into morphology and the tumor microenvironment.
We develop novel algorithms for use in pre-clinical and translational research, on our own data. Our focus lies on assessing complex structures and cell types with AI in H&E, IHC and multiplex IF, in combination with clinical, molecular and proteomics data.
We build robust GxP-compliant AI models from multi-lab data, for H&E, IHC and multiplex IF. We work in close collaboration with pathologists from Charité and other leading institutes, as well as regulatory experts, and can deploy with our own platform.
We can certify AI models with you as CDx and deploy them via third-party platforms, or our own platform for use in central labs and our partner institutions, incl. Charité Berlin. We are also working on a suite of proprietary complementary diagnostics.
Be part of our diverse and fast-growing team and work on problems that really matter, while being embedded in an exciting mix of tech, scientific research and medical device development.
